Observational study of patients co-infected with Hepatitis B and Delta viruses

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter observational study collects both prospective and retrospective data from patients co-infected with hepatitis B and Delta viruses. Participants will be monitored based on their treatment status, with regular follow-ups every six months for untreated patients and according to specific protocols for those receiving treatment. The study also involves biological sample collection for a biobank and self-administered questionnaires to gather additional data. Sub-studies may be conducted on specific patient groups, potentially involving further interventions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \> 18 years,
* Presenting a chronic HDV infection (positive serology),
* Who gave his written informed consent before any intervention and the day of inclusion at the latest,
* Affiliated to Health Insurance or to the "Aide Médicale d'Etat" (request for exemption pending).

Exclusion Criteria:

* Patient participating in another biomedical research with an exclusion period ongoing at inclusion,
* Vulnerable patient (minor, adults legally protected: under judicial protection, guardianship, or supervision, persons deprived of their liberty).
* Patients with predictable difficulties of follow-up according to the investigator.

Where it's running

• CHU of Angers
  Angers, France Recruiting
• Avicenne Hospital - Hepatology
  Bobigny, France Recruiting
• Avicenne Hospital
  Bobigny, France Recruiting
• Haut Lévêque Hospital
  Bordeaux, France Recruiting
• Estaing Hospital
  Clermont-Ferrand, France Recruiting
• Beaujon Hospital
  Clichy, France Recruiting

Study contacts

• Study coordinator: COULIBALY Fatoumata
• Email: fatoumata.coulibaly@anrs.fr
• Phone: 0144236110

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AHB-137 for chronic hepatitis B in adults on nucleotide analogue therapy

  AHB-137 is being tested to see if it is safe and effective for adults with chronic hepatitis B who are currently on nucleos(t)ide analogue therapy.

  Recruiting Phase 2 AusperBio Therapeutics Inc. · Redwood City, California and 9 other locations · NCT07654283

• Monoclonal Hepatitis B antibody safety and antiviral activity in chronic hepatitis D

  This trial tests whether HepB mAb19 can safely reduce hepatitis B-related activity to help people with chronic hepatitis D.

  Recruiting Phase 1 University of Aarhus · Aarhus and 1 other locations · NCT07610772

• Oral and gum health and saliva markers in people with hepatitis B and D

  This project will test whether gum inflammation and specific saliva and gum-fluid markers differ in adults with hepatitis B and D—both those taking bulevirtide and those not—compared with healthy adults.

  Recruiting at 2 sites Research Center of Periodontal-Systemic Interactions · Craiova and 1 other locations · NCT07491848

• Entecavir Resistance Mutations in chronic hepatitis B patients in Turkey

  This study tests whether entecavir resistance mutations can be detected in adults with chronic hepatitis B, and whether prior lamivudine exposure increases the chance of those mutations appearing.

  Recruiting at 2 sites Guven Health Group · Adana and 9 other locations · NCT07459426

• AHB-137 for HBeAg-negative chronic hepatitis B in the Asia–Pacific

  This trial tests whether AHB-137 injections can improve outcomes for adults in the Asia–Pacific with HBeAg-negative chronic hepatitis B who are already on nucleos(t)ide therapy.

  Recruiting at 9 sites Phase 2 AusperBio Therapeutics Inc. · Fitzroy, Victoria and 9 other locations · NCT07370207

• Sequential PEG-IFN for Hepatitis B After RNA-targeted Therapy

  This study tests whether starting or delaying a 24-week course of pegylated interferon helps people with chronic hepatitis B who previously used ASO/siRNA therapies.

  Recruiting at 2 sites Huashan Hospital · Beijing, China and 1 other locations · NCT06923280

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.